Posted by Michael Wonder on 02 Feb 2022
Register study on gene therapy with Zolgensma starts
1 February 2022 - Experience from clinical practice with Zolgensma, a gene therapy against certain forms of spinal muscular atrophy in children, must be documented in registries with immediate effect.
One such treatment registry for patients with spinal muscular atrophy is the SMArtCARE registry .
The pharmaceutical company regularly evaluates the anonymously recorded data and transmits the final results to the Federal Joint Committee (G-BA) by 2027 at the latest.
